Neurocrine Biosciences Inc vs Petróleo Brasileiro SA — how do they compare? Neurocrine Biosciences Inc trades at $156.86 (market cap $16.46B), while Petróleo Brasileiro SA trades at $17.98 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 6.8× Neurocrine Biosciences Inc's market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PBR | |
|---|---|---|
Market Cap | $16.46B | $112.19B |
Sector | Health | Technology |
52-Week High | $185.50 | $22.03 |
52-Week Low | $123.10 | $11.54 |
Enterprise Value | $16.48B | $172.61B |
Dividend Yield | — | 9.42% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →